Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia
Authors
Discussion
Loading...
Member takes
Implication
Retrospective cohort study reveals differential survival across therapy regimens in newly diagnosed NPM1-mutated acute myeloid leukemia, highlighting distinct prognostic risk factors.
Key Points
- To evaluate clinical outcomes and identify therapy-specific predictors of survival in patients with newly diagnosed nucleophosmin 1-mutated (NPM1mt) acute myeloid leukemia.
- Analyzed retrospective clinical data from N=396 patients with newly diagnosed NPM1mt acute myeloid leukemia treated at MD Anderson Cancer Center.
- Used Cox proportional hazards regression models to identify independent predictors of survival across high-intensity chemotherapy and hypomethylating agent (HMA) plus venetoclax regimens.
- High-intensity chemotherapy resulted in a median overall survival of 84.7 months and a 5-year rate of 53% (95% CI, 44%–61%), compared with 23.3 months and 19% (95% CI, 5%–39%) for HMA plus venetoclax.
- An alternating regimen of cladribine, low-dose cytarabine, and venetoclax with azacitidine and venetoclax yielded a superior 5-year overall survival rate versus HMA plus venetoclax in an age-matched analysis (74% vs. 24%, p = .048).
- Older age, poor performance status, FLT3-ITD mutation, and extramedullary disease predicted worse survival in patients receiving high-intensity chemotherapy, whereas only older age predicted worse outcomes with HMA plus venetoclax.
Cite This Study
Farhat et al. (2026) studied this question.